<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681640</url>
  </required_header>
  <id_info>
    <org_study_id>CS-2015-1</org_study_id>
    <nct_id>NCT02681640</nct_id>
  </id_info>
  <brief_title>uPAR PET/CT for Preoperative Staging of Breast Cancer Patients</brief_title>
  <official_title>Phase II Trial: uPAR PET/CT for Preoperative Staging of Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Curasight ApS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The sensitivity and specificity of uPAR PET/CT for preoperative detection of lymph node
      metastases in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sensitivity and specificity of uPAR PET/CT for detection of lymph node metastases will be
      tested by observer-blinded readings (two separate teams) and compared to diagnostic
      performance of conventional preoperative diagnostic workup procedures. The reference test
      will be histopathology of lymph nodes obtained by operative lymph node dissection (SN/ALND).
      Primary end point dichotomized: +/- lymph node metastases in ipsilateral axilla.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of uPAR PET/CT in identifying axillary lymph node metastases from breast cancer</measure>
    <time_frame>1 hour</time_frame>
    <description>Two separate teams of certified specialists (1 radiology and 1 nuclear medicine) will based on uPAR-PET/CT assess the presence of metastases in axillary lymph nodes (&quot;spread&quot;/&quot;no spread&quot;). Lymph Node sampling and histopathology determine true positives and true negatives.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of axillary lymph node metastasis</measure>
    <time_frame>1 hour</time_frame>
    <description>Two separate teams of certified specialists (1 radiology and 1 nuclear medicine) will based on uPAR-PET/CT assess the number of metastases in axillary lymph nodes. Lymph node sampling and histopathology determine true positives and true negatives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of distant metastases</measure>
    <time_frame>1 hour</time_frame>
    <description>Two separate teams of certified specialists (1 radiology and 1 nuclear medicine) will based on uPAR-PET/CT assess the number of distant metastases. Biopsy/follow up imaging will be used as reference.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Optimal time point for performing PET/CT following injection of 68Ga-NOTA-AE105</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>The first 5 patients will be subjected to 60 minutes of dynamic PET imaging covering the breast tumor area, starting at the time of injection. The PET scan will be divided into 12 time frames of each 5 minutes. The time frame with the best visual tumor to background contrast, will be designated as the optimal time point p.i. for uPAR-PET/CT</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>uPAR PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Ga-NOTA-AE105</intervention_name>
    <description>One injection of 68Ga-NOTA-AE105</description>
    <arm_group_label>uPAR PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography PET/CT</intervention_name>
    <description>Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT</description>
    <arm_group_label>uPAR PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-verified breast cancer

          -  Primary tumor more than 2 cm (ultrasound or clinically)

          -  The participants must be capable of understanding and giving full informed written
             consent

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation/breast feeding

          -  Weight above 140 kg

          -  Treatment with neoadjuvant chemotherapy

          -  Known allergy towards the IMP
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorthe Skovgaard, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Dorthe Skovgaard</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

